세계의 의료용 엘라스토머 시장 : 유형별, 용도별, 최종 이용 산업별, 지역별 - 예측(-2029년)

The medical elastomer market is projected to reach USD 14.27 billion by 2029 from USD 9.57 billion in 2024, at a CAGR of 8.3%. Growing demand for medical devices is fueling the demand for medical elastomers worldwide. This is a result of the increased use in disposable medical equipment, such as syringes, valves, tubing, and critical implants; artificial heart valves and artificial joints. These materials are versatile, offering durability, biocompatibility, and flexibility, making them suitable in a wide range of medical applications, such as medical tubes, bags, and gloves. The growing healthcare costs in developing economies coupled with technology advancements will further fuel the increasing demand for these critical commodities, rendering them even more indispensable to meet growing healthcare needs across the world. Additionally, the expanding population in emerging economies along with the rising prevalence of chronic diseases is creating a demand for medical elastomers.

"Based on application, implants are the fastest growing application in medical elastomer market during the forecast period, in terms of value."

Implants are the fastest growing application of medical elastomers due to increasing demand for biocompatible, durable and flexible materials in medical procedures. The rising prevalence of chronic diseases and aging populations are driving the need of durable implants in medical elastomers, as it provides superior orthopedic, dental, and soft tissue implant performance. Flexibility and comfort with least complications further make them appealing. Moreover, the ability of elastomers to be molded into complex shapes and the excellent biocompatibility enhances the future applications of customized implants, thereby further fueling the demand for medical elastomers.

"Based on end-use industry, hospitals & clinics account the largest share in medical elastomer market during the forecast period, in terms of value."

Hospitals and clinics account for the largest share in the medical elastomer market due to their heavy dependence on medical devices and equipment that utilize elastomer materials. These institutions need a wide range of products based on medical elastomers such as catheters, medical tubing, seals, gaskets, surgical gloves, and implants, in order to ensure appropriate patient care and treatment. However, the growing need for healthcare services due to growing ageing population and rising prevalence of chronic diseases such as diabetes, cardiovascular diseases, and respiratory disorders further boosts the demand for these medical devices. The properties of medical elastomers such as biocompatibility and excellent flexibility & durability along with chemical resistance makes them highly functional for various applications in hospital and clinic applications. These factors, along with the stringent regulatory requirements from healthcare authorities like FDA, ensure that hospitals and clinics are adopting high-quality elastomer-based products. All these factors combined strong healthcare needs, adherence to regulatory requirements, and the drive for advanced, reliable medical devices ensure make hospitals & clinics account largest market share by industry in the medical elastomer market.

"Based on region, Asia Pacific accounts the second largest market for medical elastomer, in terms of value."

Asia Pacific accounts the second largest market for medical elastomers because of various factors such as economic development, rapid population growth, a good healthcare sector, and increasing demand for medical devices. The rise in investments for healthcare infrastructure in emerging economies like China and India is driving the demand for adoption high-quality medical elastomers into healthcare equipments such as medical tubing, implants, and diagnostic equipment. Large and aging population in the region have added up to this demand as prevalence of chronic diseases is rising among this population. Asia Pacific is, therefore, a growth product concerning medical facility organizations dedicated to better healthcare access, positioning it as a major player in the global medical elastomer market.

In the process of determining and verifying the market size for several segments and subsegments identified through secondary research, extensive primary interviews were conducted. A breakdown of the profiles of the primary interviewees are as follows:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: Directors- 35%, Managers - 25%, and Others - 40%
• By Region: North America - 22%, Europe - 22%, Asia Pacific - 45%, RoW - 11%

The key players in this market are BASF (Germany), Dow (US), Celanese Corporation (US), Eastman Chemical Company (US), Syensqo (Belgium), Mitsubishi Chemical Group Corporation (Japan), Kuraray Co., Ltd. (Japan), ExxonMobil (US), Momentive Performance Materials (US), Envalior (Germany) and Zeon Corporation (Japan).

Research Coverage

This report segments the medical elastomer market based on type, technology, application, end-use industry, and region, and provides estimations for the overall value of the market across various regions. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, products and services, key strategies, new product launches, expansions, and mergers and acquisitions associated with the medical elastomer market.

Key benefits of buying this report

This research report focuses on various levels of analysis, including industry analysis (industry trends), market ranking analysis of top players, and company profiles, which together provide an overall view of the competitive landscape, emerging and high-growth segments of the medical elastomer market, high-growth regions, and market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Growing demand for medical devices, Technological advancements in healthcare and Prevalence of chronic diseases), restraints (High production costs), opportunities (Growing healthcare investment in emerging economies) and challenges (Stringent regulatory requirements).
• Market Penetration: Comprehensive information on the medical elastomer market offered by top players in the global medical elastomer market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the medical elastomer market.
• Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for medical elastomer market across regions.
• Market Diversification: Exhaustive information about new products, untapped regions, and recent developments in the global medical elastomer market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the medical elastomer market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 UNITS CONSIDERED
• 1.6 STAKEHOLDERS
• 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 List of key secondary sources
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 List of key primary interview participants
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of interviews with experts
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 BOTTOM-UP APPROACH
  • 2.2.2 TOP-DOWN APPROACH
• 2.3 GROWTH FORECAST
• 2.4 DATA TRIANGULATION
• 2.5 FACTOR ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS AND RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN MEDICAL ELASTOMERS MARKET
• 4.2 MEDICAL ELASTOMERS MARKET, BY TYPE, 2024 VS. 2029 (KILOTON)
• 4.3 MEDICAL ELASTOMERS MARKET, BY APPLICATION, 2024 VS. 2029 (KILOTON)
• 4.4 MEDICAL ELASTOMERS MARKET, BY END-USE INDUSTRY, 2024 VS. 2029 (KILOTON)
• 4.5 MEDICAL ELASTOMERS MARKET, BY KEY COUNTRY

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Growing demand for medical devices
    • 5.2.1.2 Technological advancements in healthcare
    • 5.2.1.3 Prevalence of chronic diseases
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 High production costs
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Growing healthcare investments in emerging economies
    • 5.2.3.2 Increasing use in minimally invasive devices
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory requirements
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT FROM NEW ENTRANTS
  • 5.3.2 THREAT OF SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF SUPPLIERS
  • 5.3.4 BARGAINING POWER OF BUYERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.4.2 BUYING CRITERIA
• 5.5 MACROECONOMIC OUTLOOK
  • 5.5.1 GDP TRENDS AND FORECASTS
• 5.6 IMPACT OF AI/GENAI
• 5.7 VALUE CHAIN ANALYSIS
• 5.8 ECOSYSTEM ANALYSIS
• 5.9 CASE STUDY ANALYSIS
  • 5.9.1 KENT ELASTOMERS HELPED IN TRANSITIONING TO NON-LATEX MEDICAL COMPONENTS
  • 5.9.2 COOPER UNIVERSITY HOSPITAL BOOSTS POLYPHENYLENE ETHER RESILIENCE WITH DENTEC SAFETY COMFORT-AIRNXMD
  • 5.9.3 TECNOFLON FKM AS HIGH-PERFORMANCE ALTERNATIVE TO SILICONE IN ORTHOPEDIC APPLICATIONS
• 5.10 REGULATORY LANDSCAPE
  • 5.10.1 ENVIRONMENTAL REGULATIONS
  • 5.10.2 NORTH AMERICA
  • 5.10.3 ASIA PACIFIC
  • 5.10.4 EUROPE
  • 5.10.5 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.11 TECHNOLOGY ANALYSIS
  • 5.11.1 KEY TECHNOLOGIES
    • 5.11.1.1 Extrusion technology
    • 5.11.1.2 Compression molding
  • 5.11.2 COMPLEMENTARY TECHNOLOGIES
    • 5.11.2.1 Co-extrusion technology
  • 5.11.3 ADJACENT TECHNOLOGIES
    • 5.11.3.1 Additive manufacturing technology
• 5.12 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.13 TRADE ANALYSIS
  • 5.13.1 IMPORT SCENARIO (HS CODE 391000)
  • 5.13.2 EXPORT SCENARIO (HS CODE 391000)
  • 5.13.3 IMPORT SCENARIO (HS CODE 400270)
  • 5.13.4 EXPORT SCENARIO (HS CODE 400270)
• 5.14 KEY CONFERENCES AND EVENTS, 2024-2025
• 5.15 PRICING ANALYSIS
  • 5.15.1 AVERAGE SELLING PRICE TREND OF MEDICAL ELASTOMERS, BY REGION
  • 5.15.2 AVERAGE SELLING PRICE TREND OF MEDICAL ELASTOMERS, BY APPLICATION
  • 5.15.3 AVERAGE SELLING PRICE TREND OF MEDICAL ELASTOMERS, BY END-USE INDUSTRY
• 5.16 INVESTMENT AND FUNDING SCENARIO
• 5.17 PATENT ANALYSIS
  • 5.17.1 INTRODUCTION
  • 5.17.2 LEGAL STATUS OF PATENTS
  • 5.17.3 JURISDICTION ANALYSIS
• 5.18 LIST OF POTENTIAL CUSTOMERS

6 MEDICAL ELASTOMERS MARKET, BY TECHNOLOGY

• 6.1 INTRODUCTION
• 6.2 EXTRUSION
• 6.3 INJECTION MOLDING
• 6.4 COMPRESSION MOLDING
• 6.5 OTHER TECHNOLOGIES

7 MEDICAL ELASTOMERS MARKET, BY END-USE INDUSTRY

• 7.1 INTRODUCTION
• 7.2 HOSPITALS & CLINICS
  • 7.2.1 RISING PREVALENCE OF CHRONIC DISEASES TO DRIVE MARKET
• 7.3 PHARMACEUTICAL
  • 7.3.1 CRUCIAL ROLE OF ELASTOMERS IN PACKAGING AND DRUG DELIVERY SYSTEMS TO PROPEL ADOPTION
• 7.4 MEDICAL DEVICE MANUFACTURING
  • 7.4.1 RISING DEMAND FOR ADVANCED MEDICAL DEVICES TO SUPPORT MARKET GROWTH
• 7.5 OTHER END-USE INDUSTRIES

8 MEDICAL ELASTOMERS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 MEDICAL TUBING
  • 8.2.1 HIGH CONSUMPTION IN ADVANCING MEDICAL TUBING SOLUTIONS TO DRIVE MARKET
• 8.3 CATHETERS
  • 8.3.1 VITAL ROLE IN PRODUCTION OF CATHETERS TO PROPEL GROWTH
• 8.4 GLOVES
  • 8.4.1 INCREASING NEED FOR PERSONAL PROTECTIVE EQUIPMENT TO INCREASE DEMAND
• 8.5 SYRINGES
  • 8.5.1 PRE-FILLED SYRINGES
    • 8.5.1.1 Reduce risk of dosing errors-key factor driving adoption
  • 8.5.2 NON-PRE-FILLED SYRINGES
    • 8.5.2.1 Increasing incidence of chronic diseases to propel adoption
  • 8.5.3 VIALS
    • 8.5.3.1 Increasing need for safe and effective drug delivery systems to drive market
• 8.6 MEDICAL & INFUSION BAGS
  • 8.6.1 RISE IN HOSPITAL-ACQUIRED INFECTIONS TO SUPPORT MARKET GROWTH
• 8.7 IMPLANTS
  • 8.7.1 INCREASING PREVALENCE OF AGE-RELATED HEALTH CONDITIONS TO DRIVE MARKET
• 8.8 OTHER APPLICATIONS

9 MEDICAL ELASTOMERS MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 THERMOSET ELASTOMERS
  • 9.2.1 SILICONE
    • 9.2.1.1 Efficient alternative to latex products in medical and pharmaceutical applications
    • 9.2.1.2 High temperature vulcanized
    • 9.2.1.3 Liquid silicone rubber
    • 9.2.1.4 Room temperature vulcanized
  • 9.2.2 ETHYLENE PROPYLENE DIENE MONOMER
    • 9.2.2.1 Suitable for various medical applications-key factor supporting market growth
  • 9.2.3 OTHER THERMOSET ELASTOMERS
• 9.3 THERMOPLASTIC ELASTOMERS
  • 9.3.1 THERMOPLASTIC POLYURETHANE
    • 9.3.1.1 Provide efficiency in manufacturing complex designs using extrusion and molding techniques
  • 9.3.2 STYRENE BLOCK COPOLYMERS
    • 9.3.2.1 Biostability of SBC increases utility in medical applications-key factor driving market growth
  • 9.3.3 OTHER THERMOPLASTIC ELASTOMERS

10 MEDICAL ELASTOMERS MARKET, BY REGION

• 10.1 INTRODUCTION
• 10.2 NORTH AMERICA
  • 10.2.1 US
    • 10.2.1.1 Rising healthcare spending to drive market
  • 10.2.2 CANADA
    • 10.2.2.1 Expanding healthcare system to support market growth
  • 10.2.3 MEXICO
    • 10.2.3.1 Government initiatives and growth of healthcare sector to drive market
• 10.3 ASIA PACIFIC
  • 10.3.1 CHINA
    • 10.3.1.1 Growing aging population to drive market
  • 10.3.2 JAPAN
    • 10.3.2.1 Increased focus on infection control and patient safety to propel market
  • 10.3.3 INDIA
    • 10.3.3.1 Increasing investments in healthcare sector to drive market
  • 10.3.4 SOUTH KOREA
    • 10.3.4.1 Rising demand for high quality medical devices to drive market
  • 10.3.5 INDONESIA
    • 10.3.5.1 Rising incidence of chronic diseases to drive market
  • 10.3.6 REST OF ASIA PACIFIC
• 10.4 EUROPE
  • 10.4.1 GERMANY
    • 10.4.1.1 Increased investments in R&D to drive market
  • 10.4.2 UK
    • 10.4.2.1 Rising geriatric population to support market growth
  • 10.4.3 FRANCE
    • 10.4.3.1 Presence of significant medical device manufacturers to propel market
  • 10.4.4 ITALY
    • 10.4.4.1 Rising demand for medical devices from public hospitals to increase demand
  • 10.4.5 SPAIN
    • 10.4.5.1 Increasing investments in healthcare infrastructure to propel market
  • 10.4.6 REST OF EUROPE
• 10.5 MIDDLE EAST & AFRICA
  • 10.5.1 GCC COUNTRIES
    • 10.5.1.1 Saudi Arabia
      • 10.5.1.1.1 Need for advanced medical technologies to drive market
    • 10.5.1.2 Rest of GCC countries
  • 10.5.2 SOUTH AFRICA
    • 10.5.2.1 Outbreak of contagious diseases to drive market
  • 10.5.3 REST OF MIDDLE EAST & AFRICA
• 10.6 SOUTH AMERICA
  • 10.6.1 BRAZIL
    • 10.6.1.1 Largest market for medical elastomers in South America
  • 10.6.2 ARGENTINA
    • 10.6.2.1 Growing demand for medical devices to drive market
  • 10.6.3 REST OF SOUTH AMERICA

11 COMPETITIVE LANDSCAPE

• 11.1 OVERVIEW
• 11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2019-2024
• 11.3 REVENUE ANALYSIS, 2021-2023
• 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.4.1 NORTH AMERICA: MARKET SHARE ANALYSIS, BY APPLICATION, 2023
  • 11.4.2 EUROPE: MARKET SHARE ANALYSIS, BY APPLICATION, 2023
  • 11.4.3 ASIA PACIFIC: MARKET SHARE ANALYSIS, BY APPLICATION, 2023
  • 11.4.4 DOW
  • 11.4.5 EXXON MOBIL CORPORATION
  • 11.4.6 CELANESE CORPORATION
  • 11.4.7 BASF
  • 11.4.8 WACKER CHEMIE AG
• 11.5 COMPANY VALUATION AND FINANCIAL METRICS
• 11.6 BRAND/PRODUCT COMPARISON
  • 11.6.1 MEDICAL ELASTOMERS MARKET: BRAND/PRODUCT COMPARISON ANALYSIS
  • 11.6.2 ELASTOLLAN
  • 11.6.3 ENGAGE 8480K HEALTH+
  • 11.6.4 HYTREL
  • 11.6.5 ECDEL
• 11.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 11.7.1 STARS
  • 11.7.2 EMERGING LEADERS
  • 11.7.3 PERVASIVE PLAYERS
  • 11.7.4 PARTICIPANTS
  • 11.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 11.7.5.1 Overall company footprint
    • 11.7.5.2 Region footprint
    • 11.7.5.3 Technology footprint
    • 11.7.5.4 Type Footprint
    • 11.7.5.5 Application footprint
    • 11.7.5.6 Industry footprint
• 11.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 11.8.1 PROGRESSIVE COMPANIES
  • 11.8.2 RESPONSIVE COMPANIES
  • 11.8.3 DYNAMIC COMPANIES
  • 11.8.4 STARTING BLOCKS
  • 11.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 11.8.5.1 Detailed list of startups/SMEs
    • 11.8.5.2 Competitive benchmarking of startups/SMEs
• 11.9 COMPETITIVE SCENARIO
  • 11.9.1 PRODUCT LAUNCHES
  • 11.9.2 DEALS
  • 11.9.3 EXPANSIONS
  • 11.9.4 OTHER DEVELOPMENTS

12 COMPANY PROFILES

• 12.1 KEY PLAYERS
  • 12.1.1 DOW
    • 12.1.1.1 Business overview
    • 12.1.1.2 Products offered
    • 12.1.1.3 Recent developments
      • 12.1.1.3.1 Other developments
    • 12.1.1.4 MnM view
      • 12.1.1.4.1 Key strengths
      • 12.1.1.4.2 Strategic choices
      • 12.1.1.4.3 Weaknesses and competitive threats
  • 12.1.2 EXXON MOBIL CORPORATION
    • 12.1.2.1 Business overview
    • 12.1.2.2 Products offered
    • 12.1.2.3 MnM view
      • 12.1.2.3.1 Key strengths
      • 12.1.2.3.2 Strategic choices
      • 12.1.2.3.3 Weaknesses and competitive threats
  • 12.1.3 CELANESE CORPORATION
    • 12.1.3.1 Business overview
    • 12.1.3.2 Products offered
    • 12.1.3.3 Recent developments
      • 12.1.3.3.1 Deals
    • 12.1.3.4 MnM view
      • 12.1.3.4.1 Key strengths
      • 12.1.3.4.2 Strategic choices
      • 12.1.3.4.3 Weaknesses and competitive threats
  • 12.1.4 BASF
    • 12.1.4.1 Business overview
    • 12.1.4.2 Products offered
    • 12.1.4.3 Recent developments
      • 12.1.4.3.1 Expansions
    • 12.1.4.4 MnM view
      • 12.1.4.4.1 Key strengths
      • 12.1.4.4.2 Strategic choices
      • 12.1.4.4.3 Weaknesses and competitive threats
  • 12.1.5 WACKER CHEMIE AG
    • 12.1.5.1 Business overview
    • 12.1.5.2 Products offered
    • 12.1.5.3 Recent developments
      • 12.1.5.3.1 Product launches
      • 12.1.5.3.2 Expansions
    • 12.1.5.4 MnM view
      • 12.1.5.4.1 Key strengths
      • 12.1.5.4.2 Strategic choices
      • 12.1.5.4.3 Weaknesses and competitive threats
  • 12.1.6 EASTMAN CHEMICAL COMPANY
    • 12.1.6.1 Business overview
    • 12.1.6.2 Products offered
    • 12.1.6.3 MnM view
      • 12.1.6.3.1 Key strengths
      • 12.1.6.3.2 Strategic choices
      • 12.1.6.3.3 Weaknesses and competitive threats
  • 12.1.7 SYENSQO
    • 12.1.7.1 Business overview
    • 12.1.7.2 Products offered
    • 12.1.7.3 Recent developments
      • 12.1.7.3.1 Other developments
    • 12.1.7.4 MnM view
      • 12.1.7.4.1 Key strengths
      • 12.1.7.4.2 Strategic choices
      • 12.1.7.4.3 Weaknesses and competitive threats
  • 12.1.8 KURARAY CO., LTD
    • 12.1.8.1 Business overview
    • 12.1.8.2 Products offered
    • 12.1.8.3 MnM view
      • 12.1.8.3.1 Key strengths
      • 12.1.8.3.2 Strategic choices
      • 12.1.8.3.3 Weaknesses and competitive threats
  • 12.1.9 MITSUBISHI CHEMICAL GROUP CORPORATION
    • 12.1.9.1 Business overview
    • 12.1.9.2 Products offered
    • 12.1.9.3 Recent developments
      • 12.1.9.3.1 Other developments
      • 12.1.9.3.2 Deals
    • 12.1.9.4 MnM view
  • 12.1.10 MOMENTIVE PERFORMANCE MATERIALS
    • 12.1.10.1 Business overview
    • 12.1.10.2 Products offered
    • 12.1.10.3 MnM view
  • 12.1.11 ENVALIOR
    • 12.1.11.1 Business overview
    • 12.1.11.2 Products offered
  • 12.1.12 ZEON CORPORATION
    • 12.1.12.1 Business overview
    • 12.1.12.2 Products offered
  • 12.1.13 THE LUBRIZOL CORPORATION
    • 12.1.13.1 Business overview
    • 12.1.13.2 Products offered
    • 12.1.13.3 MnM view
• 12.2 OTHER PLAYERS
  • 12.2.1 KRATON CORPORATION
  • 12.2.2 FOSTER CORPORATION
  • 12.2.3 BIOMERICS
  • 12.2.4 RTP COMPANY
  • 12.2.5 ROMAR ENGINEERING
  • 12.2.6 THE RUBBER GROUP
  • 12.2.7 KENT ELASTOMER PRODUCTS
  • 12.2.8 RAUMEDIC AG
  • 12.2.9 THE HYGENIC COMPANY, LLC
  • 12.2.10 HEXAPOL AB
  • 12.2.11 TEKNI-PLEX, INC
  • 12.2.12 TRINSEO
  • 12.2.13 TRELLEBORG AB
  • 12.2.14 SAINT-GOBAIN

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS